ReviewInternational journal of nanomedicine2026
Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) diseases are increasing in prevalence worldwide and represent a major public health burden. However, current treatments remain limited and are often associated with adverse effects, highlighting the need for innovative therapeutic strategies. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have emerged as promising candidates because of their anti-inflammatory, immunomodulatory, and regenerative properties. Accumulating evidence indicates that many of their therapeutic effects are mediated by extracellular vesicles, particularly hUC-MSC-derived exosomes (hUC-MSC-exos). This review first summarizes the composition and therapeutic mechanisms of hUC-MSCs and hUC-MSC-exos in GI diseases. We discuss in detail their roles in immune regulation, gut microbiota modulation, and metabolic regulation. Additionally, we highlight their potential as natural therapeutic agents and drug delivery vehicles, as well as recent engineering strategies designed to improve their therapeutic efficacy, stability, storage, and targeted delivery. We further summarize current clinical evidence. Despite encouraging preclinical findings, clinical evidence remains limited, and their effects in gastrointestinal tumors are context-dependent, with both tumor-promoting and tumor-suppressive activities reported. Further studies are needed to characterize the functional components of hUC-MSCs and hUC-MSC-exos and to clarify their effects on gastrointestinal tumors through rigorous in vivo investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.